Lupin Pharmaceuticals, Inc.
Lupin Pharmaceuticals, Inc., a prominent player in the global pharmaceutical industry, is headquartered in the United States. Founded in 1968, the company has established a strong presence in various operational regions, including North America, Europe, and Asia. Specialising in generic and branded medications, Lupin focuses on therapeutic areas such as cardiovascular, diabetes, and central nervous system disorders. With a commitment to innovation, Lupin has achieved significant milestones, including numerous FDA approvals and a robust pipeline of products. Their core offerings, which include high-quality generics and specialty pharmaceuticals, are distinguished by their efficacy and affordability. As a leading manufacturer, Lupin Pharmaceuticals is recognised for its market position, consistently ranking among the top generic drug producers in the US, reflecting its dedication to improving patient outcomes worldwide.
DitchCarbon Score
How does Lupin Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Lupin Pharmaceuticals, Inc.'s score of 31 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Lupin Pharmaceuticals, Inc.'s reported carbon emissions
Lupin Pharmaceuticals, Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. Without emissions figures, it is challenging to assess their carbon footprint or the scope of their emissions (Scope 1, 2, or 3). However, the pharmaceutical industry is increasingly focusing on sustainability and climate commitments, and it is likely that Lupin is engaging in initiatives to align with these trends. As the industry evolves, companies like Lupin may adopt more transparent reporting practices and set ambitious targets to reduce their environmental impact.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Lupin Pharmaceuticals, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
